Health alert of the risk of pancreatitis of two antithyroid drugs

The Spanish Agency for Medicines and Health Products (Aemps) has warned that there have been reports of acute pancreatitis associated with the use of carbimazole and aide drugs


Health

Blisters of different types of drugs. THE WORLD

Its use has also been associated in pregnant women with an increased risk of congenital malformations

The Spanish Agency for Medicines and Health Products (Aemps) has warned that there have been reports of acute pancreatitis associated with the use of carbimazole and thiamazole drugs, indicated in situations in which a reduction in thyroid function, such as hyperthyroidism, is necessary .

In an informative note, the Aemps recommends "avoiding as far as possible" the use of these drugs in pregnant women, since recently available information has been evaluated related to the risk of congenital malformations associated with its use during pregnancy.

In most of the reported cases of acute pancreatitis, the suspension of treatment improved the patient's clinical situation.

Therefore, patients who develop this condition during treatment with carbimazole and thiamazole, marketed under the names of Neo-tomizol and Tirodril , should suspend it "immediately" and not be treated with these drugs again.

Although the results of epidemiological studies are not homogeneous, those of larger population indicate an increased risk of congenital malformations with the use of these drugs during pregnancy with respect to non-use.

Exposure during the first trimester and administration of higher doses are considered risk factors.

Reported malformations include congenital cutaneous aplasia, craniofacial malformations, omphalocele (defect in the abdominal wall in which the intestines, liver or other organs leave the abdomen through the navel), esophageal atresia (part of the esophagus does not develop properly), anomaly of the omphalomesenteric duct and ventricular septal defect.

If treatment during pregnancy is essential, Aemps advises to use the minimum effective dose and to carry out a close maternal, fetal and neonatal monitoring.

In addition, women of childbearing age should be warned of the need to use effective contraception during treatment and of going to the doctor should they wish to plan a pregnancy.

According to the criteria of

Know more

REF: https://www.elmundo.es/ciencia-y-salud/salud/2019/02/12/5c62aa98fdddff4f368b467f.html